Current Report Filing (8-k)
April 27 2023 - 8:55AM
Edgar (US Regulatory)
0001855644
false
0001855644
2023-04-27
2023-04-27
0001855644
us-gaap:CommonClassAMember
2023-04-27
2023-04-27
0001855644
us-gaap:WarrantMember
2023-04-27
2023-04-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Warrants [Member]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT
OF 1934
Date of Report (Date of earliest
event reported): April 27, 2023
Zura
Bio Limited
(Exact name of registrant
as specified in its charter)
| Cayman Islands |
|
001-40598 |
|
98-1725736 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
4225 Executive Square, Suite
600
La Jolla, CA 92037
(Address of principal executive
offices, including zip code)
(858) 247-0520
(Registrant’s telephone
number, including area code)
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
| Class A Ordinary Shares, par value $0.0001 per share |
|
ZURA |
|
The Nasdaq Stock Market |
| Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share |
|
ZURAW |
|
The Nasdaq Stock Market |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 7.01 |
Regulation FD Disclosure. |
On April 27, 2023, Zura
Bio Limited, a Cayman Islands exempted company (the “Company”) issued the press release attached hereto as Exhibit 99.1 to
this Current Report on Form 8-K.
Furnished as Exhibit 99.2 hereto and incorporated
into this Item 7.01 by reference is an investor presentation (the “Investor Presentation”) that the Company has prepared for
use in presentations to potential PIPE investors.
By filing this Current Report on Form 8-K
and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report
that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Investor
Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission
(“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time.
The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do
so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents
with the SEC, through press releases or through other public disclosure.
The information presented in Item 7.01 of
this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically
incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
| Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 27, 2023
| |
Zura Bio Limited |
|
| |
|
|
|
| |
By: |
/s/ Someit Sidhu |
|
| |
|
Someit Sidhu |
|
| |
|
Chief Executive Officer |
|
Zura Bio (NASDAQ:ZURA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Zura Bio (NASDAQ:ZURA)
Historical Stock Chart
From Jan 2024 to Jan 2025
